|
Synonyms: Alhemo® | Anti-TFPI | mab2021 | NN7415
concizumab is an approved drug (Health Canada (2023))
Compound class:
Antibody
Comment: Concizumab is a clinical stage anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. It is a humanised IgG4 construct that was developed by Novo Nordisk as a novel therapeutic for genetic bleeding disorders [2]. Concizumab binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI and blocks its interaction with the active site of FXa [1]. TFPI is an endogenous anticoagulant protein whose pharmacological inhibition restores hemostasis [7].
|
| Bioactivity Comments |
| In vitro, concizumab demonstrates binding to cell surface TFPI on EA.hy926 cells and neutralises TFPI inhibition of Factor X activation [3]. It cross-reacts with rabbit TFPI, but not with rat TFPI. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
